59 3.2.1 L'intégration de l'index et des adaptateurs lors de la PCR 2, ., p.60 ,
URL : https://hal.archives-ouvertes.fr/halshs-00593227
Core Binding Factor ? -Myosin Heavy chain 11 CBL Cluster of Différenciation Comma Separated Value Cycle threshold DNA (cytosine-5)-methyl-transferase 3 alpha DNTP Erythroblastosis virus E26 FMS-like tyrosine kinase, Immunoglobulin Enhancer binding factors E12/E47 (=TCF3).. Flow cell FISH ................... Fluorescence in Situ Hybridization FLT3 GATA binding protein 2 ,
German Multicenter study group for Adult Acute Lymphoblastic Leukemia High Resolution Melting IDH1 et 2, Tyrosine-protein kinase Kit KRAS .................. v-Ki-ras2 Kirsten rat sarcoma viral Leucémie Aigüe Lymphoïde Page ,
Organisation Mondiale, Peripheric Blood Lymphocytes PBX1 .................. Pre-B cell leukemia transcription factor 1 ,
Phage X (Illumina) Promyelocytic leukemia-Retinoic acid receptor alpha, Stem Cell Factor SF3B1 ................ Splicing factor 3B subunit 1 ,
Single Molecule Real Time SNP, Single Nucleotide Polymorphism SRSF2 ................ Serine/arginine-Rich Splicing Factor ,
Signal Transducer and Activator of Transcription TCF3, Transcription Factor, vol.3, issue.=E2A ,
Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes, Journal of Clinical Oncology, vol.30, issue.27, pp.30-3376, 2012. ,
DOI : 10.1200/JCO.2011.40.7379
Acute myeloid leukemia: Epidemiology and etiology, Cancer, vol.9, issue.9, pp.2099-107, 2006. ,
DOI : 10.1002/cncr.22233
Acute Myeloid Leukemia, Hematology, vol.2004, issue.1, pp.98-117, 2004. ,
DOI : 10.1182/asheducation-2004.1.98
Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia, Nature Genetics, vol.27, issue.3, pp.263-70, 2001. ,
DOI : 10.1038/85820
High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia., Blood, pp.822-831, 2012. ,
Genomics of AML : Clinical Applications of Next-Generation Sequencing ? Am Soc Hematol, pp.30-35, 2011. ,
WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues - International Agency for Research on cancer, 2008. ,
The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties, Blood, vol.92, issue.7, pp.2322-2355, 1998. ,
Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia, Blood, vol.93, pp.3167-3215, 1999. ,
Core-binding factor: a central player in hematopoiesis and leukemia Independent prognostic variables in acute myeloid leukaemia. -Blood Rev, Cancer, vol.59, pp.1789-1793, 1999. ,
Chromosome Aberrations, Gene Mutations and Expression Changes, and Prognosis in Adult Acute Myeloid Leukemia ? ASH _ Hematology, 2006. ,
The role of gemtuzumab ozogamicin in acute leukaemia therapy, British Journal of Haematology, vol.240, issue.0, 2006. ,
DOI : 10.1038/sj.leu.2402749
Internal tandem duplication of the flt3 gene found in acute myeloid leukemia, Leukemia, vol.10, issue.12, pp.1911-1919, 1996. ,
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease, Blood, vol.100, issue.1, pp.59-66, 2002. ,
DOI : 10.1182/blood.V100.1.59
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm, Blood, vol.100, issue.13, pp.4372-80, 2002. ,
DOI : 10.1182/blood-2002-05-1440
Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype, Blood, vol.106, issue.12, pp.3733-3742, 2005. ,
DOI : 10.1182/blood-2005-06-2248
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations, Blood, vol.106, issue.12, pp.3740-3746, 2005. ,
DOI : 10.1182/blood-2005-05-2164
Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML), Blood, vol.107, issue.10, pp.4011-4031, 2006. ,
DOI : 10.1182/blood-2005-08-3167
Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome, Nature Genetics, vol.27, issue.3, pp.263-70, 2001. ,
DOI : 10.1038/85820
Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis, British Journal of Cancer, vol.18, issue.8, pp.1343-1349, 2009. ,
DOI : 10.1073/pnas.94.2.569
Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome, New England Journal of Medicine, vol.361, issue.11, pp.1058-66, 2009. ,
DOI : 10.1056/NEJMoa0903840
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate, Nature, vol.50, issue.7274, pp.739-783, 2009. ,
DOI : 10.1038/nature08617
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2818760
Mutations in Acute Myeloid Leukemia, New England Journal of Medicine, vol.363, issue.25, pp.2424-2457, 2010. ,
DOI : 10.1056/NEJMoa1005143
Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group, British Journal of Haematology, vol.1, issue.4, pp.451-459, 1976. ,
DOI : 10.1111/j.1365-2141.1976.tb03563.x
Frequent pathway mutations of splicing machinery in myelodysplasia, Nature, vol.451, issue.7367, pp.64-73, 2011. ,
DOI : 10.1038/nature10496
International scoring system for evaluating prognosis in myelodysplastic syndromes, Blood, vol.89, pp.2079-88, 1997. ,
A new method for sequencing DNA., Proceedings of the National Academy of Sciences, vol.74, issue.2, pp.99-103, 1977. ,
DOI : 10.1073/pnas.74.2.560
DNA sequencing with chain-terminating inhibitors, Proceedings of the National Academy of Sciences, vol.74, issue.12, pp.104-112, 1977. ,
DOI : 10.1073/pnas.74.12.5463
Sequencing technologies ??? the next generation, Nature Reviews Genetics, vol.37, issue.1, pp.31-46, 2010. ,
DOI : 10.1038/nrg2626
Anticipating the 1,000 dollar genome, Genome Biology, vol.7, issue.7, p.112, 2006. ,
DOI : 10.1186/gb-2006-7-7-112
The real cost of sequencing: higher than you think!, Genome Biology, vol.12, issue.8, p.125, 2011. ,
DOI : 10.1186/gm205
Field guide to next-generation DNA sequencers, Molecular Ecology Resources, vol.463, issue.Suppl. 1, pp.759-769, 2011. ,
DOI : 10.1111/j.1755-0998.2011.03024.x
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer, Nature, vol.102, issue.7404, pp.532-538, 2012. ,
DOI : 10.1038/nature11156
Next-generation sequencing: ready for the clinics?, Clinical Genetics, vol.21, issue.5, pp.503-513 ,
DOI : 10.1111/j.1399-0004.2012.01865.x
Unraveling the Genetics of Cancer: Genome Sequencing and Beyond, Annual Review of Genomics and Human Genetics, vol.12, issue.1, pp.407-437, 2011. ,
DOI : 10.1146/annurev-genom-082509-141532
Chromosomal translocations: revisited yet again, Blood, vol.112, issue.6, pp.2183-2192, 2008. ,
DOI : 10.1182/blood-2008-04-097931
Cytogenetics in acute leukemia, Blood Reviews, vol.18, issue.2, pp.115-151, 2004. ,
DOI : 10.1016/S0268-960X(03)00040-7
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet, Blood, vol.115, issue.3, pp.453-74, 2010. ,
DOI : 10.1182/blood-2009-07-235358
Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia, Journal of Clinical Oncology, vol.30, issue.36, pp.4515-4538, 2012. ,
DOI : 10.1200/JCO.2012.43.4738
Chromosome Aberrations, Gene Mutations and Expression Changes, and Prognosis in Adult Acute Myeloid Leukemia, Hematology, vol.2006, issue.1, pp.169-177, 2006. ,
DOI : 10.1182/asheducation-2006.1.169
in Myeloid Cancers, New England Journal of Medicine, vol.360, issue.22, pp.2289-301, 2009. ,
DOI : 10.1056/NEJMoa0810069
Clinical Effect of Point Mutations in Myelodysplastic Syndromes, New England Journal of Medicine, vol.364, issue.26, pp.2496-506, 2011. ,
DOI : 10.1056/NEJMoa1013343
Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression, Journal of Clinical Oncology, vol.29, issue.15, pp.1971-1980, 2011. ,
DOI : 10.1200/JCO.2010.31.8576
ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome, Leukemia, vol.27, issue.1, 2012. ,
DOI : 10.1056/NEJMoa1005143
Mutations in Acute Myeloid Leukemia, Journal of Clinical Oncology, vol.29, issue.21 ,
DOI : 10.1200/JCO.2011.35.4894
P052 Acquired mutations in TET2 are common in myelodysplastic syndromes, Leukemia Research, vol.33, pp.838-880, 2009. ,
DOI : 10.1016/S0145-2126(09)70132-8
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs), Blood, vol.114, issue.15, pp.3285-91, 2009. ,
DOI : 10.1182/blood-2009-04-215814
Association of TET2 Alterations with NPM1 Mutations and Prognostic Value in De Novo Acute Myeloid Leukemia (AML), ASH Annual Meeting Abstracts, vol.114, p.163, 2009. ,
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome, Blood, vol.119, issue.9, pp.2114-2135, 2012. ,
DOI : 10.1182/blood-2011-08-375758
KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival, Blood, vol.107, issue.5, pp.1791-1800, 2006. ,
DOI : 10.1182/blood-2005-04-1466
Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study, Blood, vol.107, issue.9, pp.3463-3471, 2006. ,
DOI : 10.1182/blood-2005-09-3640
Mutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study, Journal of Clinical Oncology, vol.26, issue.28, pp.26-4603, 2008. ,
DOI : 10.1200/JCO.2007.14.0418
Mutations in the ras proto-oncogenes in patients with myelodysplastic syndromes ,
High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms, Haematologica, vol.98, issue.2, pp.98-113, 2013. ,
DOI : 10.3324/haematol.2012.072538
Metabolic Enzymes as Oncogenes or Tumor Suppressors, New England Journal of Medicine, vol.360, issue.8, pp.813-818, 2009. ,
DOI : 10.1056/NEJMe0810213
Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value, Blood, vol.116, issue.12, pp.116-2122, 2010. ,
DOI : 10.1182/blood-2009-11-250878
Mutation in Myelodysplasia with Ring Sideroblasts, New England Journal of Medicine, vol.365, issue.15, pp.1384-1395, 2011. ,
DOI : 10.1056/NEJMoa1103283
Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes, Blood, vol.119, issue.15, pp.3578-3584, 2012. ,
DOI : 10.1182/blood-2011-12-399337
SETBP1 mutation analysis in 944 patients with MDS and AML Leukemia advance online publication, 2013. ,
Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases, Haematologica, vol.97, issue.12, pp.97-1890, 2012. ,
DOI : 10.3324/haematol.2012.065375
Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies, Annals of Hematology, vol.24, issue.11 Suppl ,
DOI : 10.1007/s00277-010-0920-6
The UCSC Genome Browser database: extensions and updates 2011, Nucleic Acids Research, vol.40, issue.D1, pp.918-923 ,
DOI : 10.1093/nar/gkr1055
Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia, Leukemia Research, vol.36, issue.3, pp.316-339, 2012. ,
DOI : 10.1016/j.leukres.2011.11.002
Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations, Genes, Chromosomes and Cancer, vol.99, issue.7, pp.689-95, 2012. ,
DOI : 10.1002/gcc.21955
High-Throughput Sequencing Detects Minimal Residual Disease in Acute T Lymphoblastic Leukemia, Science Translational Medicine, vol.4, issue.134, pp.134-63, 2012. ,
DOI : 10.1126/scitranslmed.3003656